Impairment test (Tables) |
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2025 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Impairment Test [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Schedule of impairment loss |
The impairment reversal as of December 31, 2025 was allocated to the impaired assets as follows:
(*) Comprised of owned and right-of-use assets.
The impairment loss as of September 30, 2023 was allocated as detailed below:
(*) Comprised of owned and right-of-use assets.
(**) Impairment loss in the amount of US$ 28.5 million was included in Other operating expenses.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||